Tabimorelin
Also known as: NN703, Ipamorelin analog
Tabimorelin is a synthetic ghrelin receptor agonist that stimulates growth hormone release from the pituitary gland. This peptide was developed as a potential treatment for growth hormone deficiency and cachexia.
Tabimorelin is a 817.98 g/mol research peptide. Tabimorelin is a synthetic ghrelin receptor agonist that stimulates growth hormone release from the pituitary gland. This peptide was developed as a potential treatment for growth hormone deficiency and cachexia.
Also called: NN703, Ipamorelin analog
817.98 g/mol
Molecular Weight
Daltons
1
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
100-300
Typical Dose
mcg
Overview
Tabimorelin represents an advanced synthetic compound designed to activate ghrelin receptors, triggering natural growth hormone secretion. Unlike direct growth hormone administration, tabimorelin works through the body's endogenous pathways by mimicking ghrelin, the hunger hormone that naturally signals the pituitary to release growth hormone. The peptide binds to growth hormone secretagogue receptors (GHSR) in the hypothalamus and pituitary, promoting pulsatile growth hormone release that more closely resembles natural physiological patterns. Research has focused on its potential applications in age-related growth hormone decline, muscle wasting conditions, and metabolic disorders. Tabimorelin's selective receptor binding profile aims to minimize unwanted side effects commonly associated with broader-acting growth hormone secretagogues. Studies indicate it may preserve the natural feedback mechanisms that regulate growth hormone levels, potentially offering advantages over continuous growth hormone replacement therapy.
Key Takeaways: Tabimorelin
- Strongest evidence supports Tabimorelin for growth hormone stimulation
- Research doses typically range from 100 to 300 mcg via subcutaneous
- 1 benefits with strong evidence, 3 moderate, 3 preliminary
- Half-life: 2-3 hours
- 4 cited research studies in this guide
Mechanism of Action
Tabimorelin acts as a selective agonist of the growth hormone secretagogue receptor (GHSR-1a), located primarily in the hypothalamus and pituitary gland. Upon binding, it activates intracellular calcium signaling pathways and stimulates cyclic adenosine monophosphate (cAMP) production. This cascade triggers the release of growth hormone-releasing hormone (GHRH) from the hypothalamus and directly stimulates somatotroph cells in the anterior pituitary to secrete growth hormone. The compound also influences ghrelin-mediated appetite regulation and may affect insulin-like growth factor-1 (IGF-1) production downstream.
Research Benefits
Tabimorelin at a Glance
Tabimorelin acts as a selective agonist of the growth hormone secretagogue receptor (GHSR-1a), located primarily in the hypothalamus and pituitary gland.
Growth Hormone Stimulation
Strong EvidenceIncreases endogenous growth hormone levels by 3-5 fold within 30-60 minutes of administration through selective GHSR activation
Lean Muscle Mass Preservation
Moderate EvidenceHelps maintain muscle tissue during periods of reduced caloric intake or age-related decline by promoting protein synthesis
Metabolic Rate Enhancement
Moderate EvidenceSupports increased energy expenditure and fat oxidation through growth hormone-mediated lipolytic effects
Appetite Regulation
Moderate EvidenceModulates hunger signaling through ghrelin receptor pathways, potentially supporting healthy weight management
Bone Density Support
PreliminaryMay help maintain bone mineral density by stimulating osteoblast activity and collagen synthesis
Sleep Quality Improvement
PreliminaryEnhances deep sleep phases associated with natural growth hormone release cycles
Recovery Enhancement
PreliminaryAccelerates tissue repair and reduces recovery time from physical stress through IGF-1 upregulation
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Growth hormone stimulation research | 100–300 mcg | subcutaneous |
| Metabolic function studies | 50–200 mcg | subcutaneous |
| Body composition research | 150–400 mcg | subcutaneous |
Frequency
Once daily, typically in the evening
Timing
2-3 hours before bedtime or during fasting periods for optimal growth hormone release
Cycle Length
4-8 weeks with 2-4 week breaks between cycles
Research Notes
- 1Start with lower doses to assess tolerance
- 2Timing with natural circadian rhythms enhances effectiveness
- 3Avoid administration with meals to prevent interference with ghrelin signaling
- 4Monitor blood glucose levels during research periods
Reconstitution Guide
Standard Reconstitution
Vial Size
2 mg
Bacteriostatic Water
2 mL
Concentration
10 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Tabimorelin vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 2 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C refrigerated. 30 days when reconstituted and refrigerated.
Storage Temperature
2-8°C refrigerated
Shelf Life
30 days when reconstituted and refrigerated
Important Notes
- •Use bacteriostatic water for multiple-dose vials
- •Allow to reach room temperature before injection
- •Gently swirl, do not shake vigorously
- •Store lyophilized powder at -20°C for long-term storage
Tabimorelin Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Tabimorelin Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Increased appetite and hunger
- !Mild water retention
- !Temporary hypoglycemia
- !Joint discomfort or stiffness
- !Fatigue or drowsiness
- !Headaches
- !Nausea or stomach discomfort
- !Injection site reactions
- !Dizziness
- !Sleep disturbances
Potential Interactions
- ⚡May enhance hypoglycemic effects of diabetes medications
- ⚡Could interact with cortisol-affecting medications
- ⚡May influence insulin sensitivity and glucose metabolism
- ⚡Potential interactions with thyroid hormone medications
- ⚡Could affect blood pressure medications due to fluid retention effects
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Ghrelin receptor agonists for treatment of cachexia and anorexia
Review of ghrelin receptor agonists including tabimorelin for treating muscle wasting and appetite loss in clinical conditions
Effects of growth hormone secretagogues on body composition in healthy adults
Clinical trial examining body composition changes with various growth hormone secretagogues including ghrelin analogs
Pharmacokinetics and pharmacodynamics of novel ghrelin receptor agonists
Pharmacological characterization of synthetic ghrelin receptor agonists and their growth hormone releasing properties
Ghrelin and growth hormone secretagogues in metabolic disorders
Investigation of ghrelin-based therapies for metabolic dysfunction and growth hormone deficiency states
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Tabimorelin is primarily researched for its ability to stimulate natural growth hormone release, with studies focusing on muscle preservation, metabolic function, and potential therapeutic applications for growth hormone deficiency.
Unlike direct growth hormone or GHRH analogs, tabimorelin works as a ghrelin receptor agonist, promoting more natural pulsatile growth hormone release while also affecting appetite and metabolic pathways.
Common side effects include increased appetite, mild water retention, temporary blood sugar changes, and potential joint discomfort. Most effects are dose-dependent and reversible.
Growth hormone levels typically increase within 30-60 minutes of administration, with peak effects occurring 1-2 hours post-injection. Metabolic effects may take several days to weeks of consistent use.
Tabimorelin has poor oral bioavailability and is typically administered via subcutaneous injection for research applications to ensure adequate absorption and effectiveness.
Research doses typically range from 100-400 mcg administered subcutaneously once daily, with specific protocols varying based on study objectives and subject characteristics.
Lyophilized powder should be stored at -20°C, while reconstituted solutions require refrigeration at 2-8°C and should be used within 30 days.
Long-term safety data is limited. Current research protocols typically involve cycles of 4-8 weeks with breaks between cycles to minimize potential side effects and maintain effectiveness.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.